Monte Rosa Therapeutics (GLUE) EBITDA Margin (2024 - 2026)

Monte Rosa Therapeutics' EBITDA Margin history runs 3 years deep, the most recent figure standing at 1056.33% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 111156.0% year-over-year to 1056.33%; the TTM figure through Mar 2026 stood at 3056.53% (down 305999.0% YoY), while the FY2025 annual figure was 31.61%, up 6536.0% from the prior year.
• EBITDA Margin was 1056.33% for Q1 2026 at Monte Rosa Therapeutics, up from 1679.79% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 55.24% in Q1 2025 to a low of 3001.6% in Q1 2024.
• Historically, EBITDA Margin has averaged 737.04% across 3 years, with a median of 255.11% in 2024.
• Biggest YoY gain for EBITDA Margin was 305683 bps in 2025; the steepest drop was 170024 bps in 2025.
• A 3-year view of EBITDA Margin shows it stood at 20.45% in 2024, then slumped by 8314 bps to 1679.79% in 2025, then jumped by 37 bps to 1056.33% in 2026.
• The last three EBITDA Margin figures came in at 1056.33% (Q1 2026), 1679.79% (Q4 2025), and 17.97% (Q3 2025), per Business Quant data.